Amylyx Pharmaceuticals (NASDAQ: AMLX) presented early data from the Phase 1 LUMINA trial of its investigational drug AMX0114 for amyotrophic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE